Albemarle (NYSE:ALB – Get Free Report) had its target price reduced by equities research analysts at Royal Bank Of Canada from $129.00 to $119.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the specialty chemicals company’s stock. Royal Bank Of Canada‘s price objective points to a potential upside of 20.68% from the company’s current price.
A number of other research analysts also recently weighed in on the company. BMO Capital Markets restated an “outperform” rating and issued a $175.00 price target on shares of Albemarle in a research note on Tuesday, October 6th. Zacks Research lowered Albemarle from a “hold” rating to a “strong sell” rating in a research report on Friday, October 9th. UBS Group dropped their price objective on Albemarle from $175.00 to $150.00 and set a “buy” rating on the stock in a research note on Monday, October 5th. Truist Financial reissued a “buy” rating and issued a $170.00 price objective (down from $185.00) on shares of Albemarle in a report on Friday. Finally, Weiss Ratings cut shares of Albemarle from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 23rd. Fifteen equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $177.64.
Albemarle Stock Up 0.2%
ALB stock traded up $0.24 during midday trading on Friday, hitting $98.61. The company’s stock had a trading volume of 1,084,834 shares, compared to its average volume of 2,469,517. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.09 and a quick ratio of 1.35. Albemarle has a twelve month low of $89.77 and a twelve month high of $221.00. The company’s fifty day moving average price is $108.33 and its 200 day moving average price is $148.24. The stock has a market capitalization of $11.64 billion, a P/E ratio of 23.77, a PEG ratio of 0.57 and a beta of 1.34.
Albemarle (NYSE:ALB – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The specialty chemicals company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. Albemarle had a net margin of 10.40% and a return on equity of 15.23%. The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.52 billion. During the same period in the previous year, the firm posted ($0.19) EPS. The company’s revenue for the quarter was up 18.8% on a year-over-year basis. As a group, equities research analysts predict that Albemarle will post 11.15 EPS for the current year.
Hedge Funds Weigh In On Albemarle
Institutional investors have recently bought and sold shares of the business. Sigma Planning Corp raised its stake in shares of Albemarle by 2.3% during the first quarter. Sigma Planning Corp now owns 2,952 shares of the specialty chemicals company’s stock valued at $530,000 after acquiring an additional 66 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Albemarle by 0.3% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 27,452 shares of the specialty chemicals company’s stock worth $4,928,000 after purchasing an additional 75 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Albemarle by 0.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 11,664 shares of the specialty chemicals company’s stock worth $2,082,000 after purchasing an additional 75 shares during the last quarter. Cadence Wealth Management LLC grew its stake in shares of Albemarle by 1.8% in the first quarter. Cadence Wealth Management LLC now owns 4,982 shares of the specialty chemicals company’s stock worth $894,000 after purchasing an additional 87 shares during the last quarter. Finally, Parkside Financial Bank & Trust increased its holdings in Albemarle by 7.0% in the second quarter. Parkside Financial Bank & Trust now owns 1,584 shares of the specialty chemicals company’s stock valued at $214,000 after purchasing an additional 103 shares during the period. Institutional investors and hedge funds own 92.87% of the company’s stock.
More Albemarle News
Here are the key news stories impacting Albemarle this week:
- Positive Sentiment: Albemarle reported Q3 adjusted earnings of $2.58 per share and revenue of $1.55 billion, both above analyst estimates. Revenue rose 18.8% year over year, and the company swung to a profit from a loss a year earlier. Reports attributed the earnings improvement to higher lithium prices, which also supported stronger cash flow. Article: ALB Q3 Earnings Beat Estimates on Higher Lithium Pricing
- Positive Sentiment: Scotiabank maintained a Sector Outperform rating and a $190 price target, forecasting EPS of $11.64 for FY2026 and $14.15 for FY2027—above the cited $11.15 current-year consensus estimate. Those projections point to potential earnings growth, though they are analyst forecasts rather than company guidance.
- Negative Sentiment: Barclays lowered its price target to $95 from $109 and kept an Equal Weight rating, implying downside from the cited share price. The reduced target signals a more cautious view and may limit enthusiasm following the earnings report. Barclays ratings
Albemarle Company Profile
Albemarle Corporation (NYSE: ALB) is a global specialty chemicals company headquartered in Charlotte, North Carolina. The company develops, manufactures, and markets engineered chemicals used in energy storage, transportation, refining, pharmaceuticals, agriculture, consumer products, and other industrial applications.
Albemarle is one of the world’s major producers of lithium and supplies lithium compounds, including lithium carbonate and lithium hydroxide, for use in rechargeable batteries for electric vehicles, portable electronics, and grid energy-storage systems.
Featured Articles
- Five stocks we like better than Albemarle
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
- Block by Block: Cash App Builds a Stronger Foundation
Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with MarketBeat.com's FREE daily email newsletter.
